An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma

This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.

Trial Details

NCT ID
NCT07493044
Phase
PHASE1
Sponsor
Guangzhou FineImmune Biotechnology Co., LTD.
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Super CAR-T
Locations (sample)
  • Guangzhou, Gaungdong, China|23.11667,113.25

Key Eligibility Criteria

  • Understand and voluntarily sign the informed consent form prior to participating in any trial-related activities;
  • Be between 18 and 75 years of age; gender is not restricted;
  • Diagnosed with hepatocellular carcinoma (HCC) based on histopathological or cytological examination: Patients classified as inoperable Stage IIa, I…
  • Previous failure of or intolerance to at least two lines of standard systemic therapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →